CA3131852A1 - Combination medicine - Google Patents

Combination medicine Download PDF

Info

Publication number
CA3131852A1
CA3131852A1 CA3131852A CA3131852A CA3131852A1 CA 3131852 A1 CA3131852 A1 CA 3131852A1 CA 3131852 A CA3131852 A CA 3131852A CA 3131852 A CA3131852 A CA 3131852A CA 3131852 A1 CA3131852 A1 CA 3131852A1
Authority
CA
Canada
Prior art keywords
group
substituted
combination medicine
amino
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3131852A
Other languages
English (en)
French (fr)
Inventor
Hidetoshi Murao
Hayato Ogura
Koichi Saito
Shinji Hagiwara
Takeshi Yamaura
Toshiyuki Nakatani
Hitoshi Kiyoi
Yuichi Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CA3131852A1 publication Critical patent/CA3131852A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3131852A 2019-02-28 2020-02-27 Combination medicine Abandoned CA3131852A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019035668 2019-02-28
JP2019-035668 2019-02-28
PCT/JP2020/008063 WO2020175629A1 (ja) 2019-02-28 2020-02-27 組合せ医薬

Publications (1)

Publication Number Publication Date
CA3131852A1 true CA3131852A1 (en) 2020-09-03

Family

ID=72239685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3131852A Abandoned CA3131852A1 (en) 2019-02-28 2020-02-27 Combination medicine

Country Status (8)

Country Link
US (1) US20210386768A1 (https=)
EP (1) EP3932429A4 (https=)
JP (1) JPWO2020175629A1 (https=)
CN (1) CN113490512A (https=)
AU (1) AU2020229558A1 (https=)
CA (1) CA3131852A1 (https=)
TW (1) TW202045174A (https=)
WO (1) WO2020175629A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202027749A (zh) * 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2025012029A1 (en) * 2023-07-11 2025-01-16 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising 4-(4-methyl-piperazin-1-yl)-n-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1h-indazol-3-yl}-benzamide and an antineoplastic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
CN105683167B (zh) 2013-10-16 2018-10-23 富士胶片株式会社 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
TW202027749A (zh) * 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑

Also Published As

Publication number Publication date
WO2020175629A1 (ja) 2020-09-03
AU2020229558A1 (en) 2021-09-23
US20210386768A1 (en) 2021-12-16
EP3932429A4 (en) 2022-05-11
EP3932429A1 (en) 2022-01-05
CN113490512A (zh) 2021-10-08
JPWO2020175629A1 (https=) 2020-09-03
TW202045174A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
CA3131852A1 (en) Combination medicine
JP6849711B2 (ja) Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤
AU2010286569C1 (en) Compounds and compositions as protein kinase inhibitors
US7022850B2 (en) Bicyclicpyrimidones and their use to treat diseases
EP2643313B9 (en) Quinazoline carboxamide azetidines
AU2015334917B2 (en) New compounds as NIK inhibitors
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
US10875863B2 (en) RIPK2 inhibitors and method of treating cancer with same
TW200808776A (en) Kinase inhibitors
CN105793254B (zh) 氮杂喹唑啉羧酰胺衍生物
KR20160012197A (ko) 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도
US20210220355A1 (en) Antitumor agent for acute myeloid leukemia
JP2018535235A (ja) １，３，４−チアジアゾール化合物およびがんの治療におけるその使用
CN116113406B (zh) Gas41抑制剂及其使用方法
CN105980375A (zh) 用作激酶活性调节剂的嘧啶咪唑胺
HK40057625A (en) Combinational medication
WO2024261712A1 (en) Benzamidazole diazapinone parp inhibitors and methods of use
EP4731608A1 (en) Isoindolinone-containing parp inhibitors and methods of use
HK1239664B (en) Triazolopyrimidine compounds and uses thereof
HK1239664A1 (en) Triazolopyrimidine compounds and uses thereof
HK1243407B (en) Ripk2 inhibitors and method of treating cancer with same
AU2015228386A1 (en) Cancer stem cell targeting compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210827

FZDE Discontinued

Effective date: 20240213